Pfizer Inc. (PFE)
| Market Cap | 146.48B +10.5% |
| Revenue (ttm) | 63.32B +1.4% |
| Net Income | 7.49B -5.0% |
| EPS | 1.31 -5.1% |
| Shares Out | 5.70B |
| PE Ratio | 19.61 |
| Forward PE | 9.02 |
| Dividend | $1.72 (6.69%) |
| Ex-Dividend Date | May 8, 2026 |
| Volume | 35,273,018 |
| Open | 25.73 |
| Previous Close | 25.62 |
| Day's Range | 25.47 - 25.88 |
| 52-Week Range | 23.11 - 28.75 |
| Beta | 0.30 |
| Analysts | Buy |
| Price Target | 29.19 (+13.58%) |
| Earnings Date | May 5, 2026 |
About PFE
Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. It operates in three segments: Biopharma, PC1, and Pfizer Ignite. The company offers internal medicine products, including cardiovascular metabolic diseases products under the Eliquis brand; migraine products under the Nurtec ODT/Vydura and Zavzpret brand; vaccines under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and Paxlovid for the treatment of COVID-19. It als... [Read more]
Financial Performance
In 2025, Pfizer's revenue was $62.58 billion, a decrease of -1.65% compared to the previous year's $63.63 billion. Earnings were $7.77 billion, a decrease of -3.24%.
Financial StatementsAnalyst Summary
According to 29 analysts, the average rating for PFE stock is "Buy." The 12-month stock price target is $29.19, which is an increase of 13.58% from the latest price.
News
Pfizer upgraded to Sector Perform from Underperform at RBC Capital
RBC Capital upgraded Pfizer (PFE) to Sector Perform from Underperform with a $25 price target
Pfizer upgraded to Sector Perform at RBC Capital amid more balanced risk-reward
RBC Capital analyst Trung Huynh upgraded Pfizer (PFE) to Sector Perform from Underperform with a $25 price target The firm notes that its overall thesis has not changed substantially on…
The space race is coming for pharma: Why drug development is heading to lower Earth orbit
Industries from semiconductors to fiber-optic cables stand to benefit from space research and manufacturing, but experts told CNBC that medicine could see the most immediate disruption. A flurry of co...
Pfizer Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Consistent financial outperformance and strategic transformation have positioned the business for growth beyond COVID, with a diversified pipeline in oncology, obesity, and immunology. AI and China are seen as key industry disruptors, while upcoming product launches and strong M&A execution support a high single-digit revenue CAGR from 2029.
Pfizer says FDA approves expanded indication for Hympavzi
Pfizer (PFE) announced that the U.S. FDA has approved an expanded indication for Hympavzi to include the treatment of patients with hemophilia A or B 12 years and older with…
US FDA approves Pfizer's bleeding disorder drug for children
The U.S. Food and Drug Administration has approved Pfizer's drug to prevent or reduce the frequency of bleeding episodes in children and in certain patients with hemophilia, the company said on Mond...
U.S. FDA Approves Pfizer's HYMPAVZI for the Treatment of Two Additional Hemophilia A or B Patient Populations with Significant Medical Need
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for HYMPAVZI® (marstacimab-hncq) to include the ...
Pfizer presents results from Phase 2b studies of berobenatide
Pfizer (PFE) presented detailed results from multiple Phase 2b studies of berobenatide, an investigational, potential first-in-class monthly GLP-1 receptor agonist peptide, during a late-breaking expe...
Pfizer Transcript: Study update
Phase IIb data show monthly berobenatide delivers weight loss comparable to weekly tirzepatide and superior to semaglutide, with favorable GI tolerability and no discontinuations due to adverse events. Ten phase III trials are advancing, targeting broad obesity and comorbidity indications.
Pfizer Slides: Study update
Pfizer has posted slides in relation to its latest quarterly earnings report, which was published on June 6, 2026.
Pfizer's monthly obesity shot has side-effect profile similar to Wegovy in midstage trial
Pfizer presented data on Saturday that showed a monthly dose of an experimental obesity drug it acquired through its purchase of Metsera last year had a similar side-effect profile as rival Novo Nor...
Robust Phase 2b Efficacy and Favorable Tolerability Support Monthly Dosing for Pfizer's GLP-1 RA Berobenatide
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today presented detailed results from multiple Phase 2b studies of berobenatide (PF'3944), an investigational, potential first-in-class monthly GLP-1...
Chai Discovery Announces License Agreement with Pfizer to Accelerate Drug Discovery with AI
SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the company engineering AI models to discover new molecules, announces a license agreement with Pfizer.
Why Pfizer And Eli Lilly Are Betting On This $1.3 Billion AI Drug Discovery Startup
Chai Discovery is working with major drugmakers to use its latest antibody AI model to find new therapies. Now it's in talks to raise $400 million more VC funding at a $3.4 billion valuation, Forbes h...
Pfizer Transcript: Jefferies Global Healthcare Conference 2026
The CEO outlined a strategic shift toward oncology, leveraging recent acquisitions and global partnerships, especially in China, to drive innovation. AI and organizational transformation are central to future competitiveness, while regulatory and geopolitical dynamics shape industry priorities.
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Gold...
Pfizer announces results from Cohort 3 on Bratovi with cetuximab, Folfiri
Pfizer (PFE) announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 Breakwater trial, evaluating Bratovi in combination with cetuximab and F...
Pfizer announces results from Phase 3 Talapro-3 study of Talzenna, Xtandi
Pfizer (PFE) announced detailed results from the Phase 3 Talapro-3 study of Talzenna, an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi, an androgen receptor pathway inhibitor, ...
Pfizer's BRAFTOVI Regimen Nearly Doubles Median Progression-Free Survival in Metastatic Colorectal Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced detailed progression-free and overall survival results from Cohort 3, a randomized cohort of the Phase 3 BREAKWATER trial, evaluating...
Mailbag: A Follow-Up on Pfizer & Other Questions
Two weeks ago, I said that one of my favorite stocks right now is Pfizer (PFE). The pharmaceutical giant is in the middle of a transformational period with the goal to return to growth by 2029.
TALZENNA Plus XTANDI Improves Radiographic Progression-Free Survival by More Than 50% in Metastatic Prostate Cancer
NEW YORK--(BUSINESS WIRE)--TALAPRO-3 Data Presented at ASCO.
Pfizer announces seven-year follow-up results from Phase 3 CROWN trial
Pfizer (PFE) announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating Lorbrena versus Xalkori in people with previously untreated, anaplastic lymphoma kinase-positi...
Seven-Year Analysis from Pfizer's LORBRENA CROWN Trial Shows Longest Progression-Free Survival Reported to Date in Advanced Non-Small Cell Lung Cancer
NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced unprecedented seven-year follow-up results from the Phase 3 CROWN trial evaluating LORBRENA® (lorlatinib, a third-generation ALK inhi...